Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) are self-renewable, multipotent stem cells that regulate the phenotype and function of all immune cells that participate in anti-tumor immunity. MSCs modulate the antigen-presenting properties of dendritic cells, affect chemokine and cytokine production in macrophages and CD4+ T helper cells, alter the cytotoxicity of CD8+ T lymphocytes and natural killer cells and regulate the generation and expansion of myeloid-derived suppressor cells and T regulatory cells. As plastic cells, MSCs adopt their phenotype and function according to the cytokine profile of neighboring tumor-infiltrated immune cells. Depending on the tumor microenvironment to which they are exposed, MSCs may obtain pro- and anti-tumorigenic phenotypes and may enhance or suppress tumor growth. Due to their tumor-homing properties, MSCs and their exosomes may be used as vehicles for delivering anti-tumorigenic agents in tumor cells, attenuating their viability and invasive characteristics. Since many factors affect the phenotype and function of MSCs in the tumor microenvironment, a better understanding of signaling pathways that regulate the cross-talk between MSCs, immune cells and tumor cells will pave the way for the clinical use of MSCs in cancer immunotherapy. In this review article, we summarize current knowledge on the molecular and cellular mechanisms that are responsible for the MSC-dependent modulation of the anti-tumor immune response and we discuss different insights regarding therapeutic potential of MSCs in the therapy of malignant diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs by secretion of CXCL3, HGF, and IL-6 have a role in myeloid suppressor cell (MDSC) differentiation and in this way suppress the immune system in TME.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In innate immunity, BM-MSCs express C3aR and C5aR (Complement system receptors), as anaphylatoxin receptors, for recruitment of MSCs to the sites of damage or lesions [72, 78, 79].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, human umbilical cord-derived MSC EVs (UC-MSC EVs) contain miRNA-16-5p and miRNA-3940-5p cargos that reduce the metastatic potential of tumor cells.”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies recognized that miRNAs delivered via MSC EVs were able to inhibit the metastatic potential of tumors, as well as suppress tumor growth, angiogenesis, and invasion [25].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, MSCs have the potential to enhance a pro-tumor microenvironment [25].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Razeghian, E., Margiana, R., Chupradit, S., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Shariatzadeh, S., Tosan, F., & Jarahian, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.721174 · Cited by 28
RetractedHassanzadeh, A., Altajer, A. H., Rahman, H. S., Saleh, M. M., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Zamani, M., Yaghoubi, Y., Yazdanifar, M., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686453 · Cited by 24
RetractedMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
Self-citationTherapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer
Weng, Z., Zhang, B., Wu, C., Yu, F., Han, B., Li, B., & Li, L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01141-y · Cited by 405
Davies, L. C., Heldring, N., Kadri, N., & Le Blanc, K. (2017) · Stem Cells · doi:10.1002/stem.2509 · Cited by 349
Pakravan, K., Babashah, S., Sadeghizadeh, M., Mowla, S. J., Mossahebi-Mohammadi, M., Ataei, F., Dana, N., & Javan, M. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0335-7 · Cited by 346
Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases
Gazdic, M., Volarevic, V., Arsenijevic, N., & Stojkovic, M. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9583-3 · Cited by 248
Contribution of regulatory T cells to cancer: A review
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27553 · Cited by 195
Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment
Ling, W., Zhang, J., Yuan, Z., Ren, G., Zhang, L., Chen, X., Rabson, A. B., Roberts, A. I., Wang, Y., & Shi, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1656 · Cited by 194
Cited by
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Lyu, Z., Xin, M., Oyston, D. R., Xue, T., Kang, H., Wang, X., Wang, Z., & Wang, Z. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155354 · Cited by 70
The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
Zhang, X., Zhang, H., Zhang, J., Yang, M., Zhu, M., Yin, Y., Fan, X., & Yu, F. (2022) · Immunology · doi:10.1111/imm.13592 · Cited by 71
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Metadata
- Authors
- Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V.
- Affiliations
- Regenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, FL 34684, USA
- University of Kragujevac (RS)
- University of Bern (CH)
- Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-18
- Volume
- 22
- Issue
- 22
- Pages
- 12429
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8622564
- OpenAlex
- W3213583932
- Cited by
- 67
- References
- 47
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 23 · 2023: 17 · 2022: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Crohn’s and Colitis Organization (ECCO) (“The role of galectin 3 in acute colitis”)
- Swiss National Science Foundation (IZSEZ0 185546)
- Serbian Ministry of Science (ON1275069 and ON175071)
- Faculty of Medical Sciences University of Kragujevac (MP01/18)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- mesenchymal stem cells, antitumor immunity, tumor microenvironment, dendritic cells, macrophages, CD4+ T helper cells, CD8+ T cells, natural killer cells, myeloid-derived suppressor cells, regulatory T cells, tumor homing, exosomes, cancer immunotherapy
- MeSH terms
- Cell Communication, Cell Differentiation, Dendritic Cells, Gene Expression Regulation, Humans, Immunity, Innate, Immunotherapy, Killer Cells, Natural, Macrophages, Neoplasms, T-Lymphocytes, Cytotoxic, Mesenchymal Stem Cell Transplantation, T-Lymphocytes, Regulatory, Exosomes, Tumor Microenvironment, Mesenchymal Stem Cells, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity. https://app.cochat.ai/papers/10.3390/ijms222212429
- The paper
- Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V. (2021). Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222212429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.